TNFRSF17 and Miyoshi myopathy: Additionally, MM disease characteristics, such as the presence of soluble BCMA (sBCMA), can reduce the efficacy of therapy by binding to the BsAb and thereby potentially obstructing the formation of a functional trimer complex that triggers cell death and T-cell activation17,18.